Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of Adeno-Associated Virus Gene Therapy IC-100 for rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Next Previous
Trial Profile

A phase 1/2 study of Adeno-Associated Virus Gene Therapy IC-100 for rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IC 100 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IVERIC bio

    • Most Recent Events

    • 02 Nov 2020 According to an IVERIC bio media release, the Company plans to file an IND for IC-100 with the FDA in early 2021.
    • 05 Aug 2020 According to an IVERIC bio media release, the company plans to begin enrollment during the first half of 2021.
    • 27 Feb 2020 According to an IVERIC bio media release, company plans to initiate this phase 1/2 study in fourth quarter of 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top